Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2001
10/10/2001EP1140119A1 Novel therapeutic application of low molecular weight heparin
10/10/2001EP1140118A1 Cyclic adenosine diphosphate ribose analogues for modulating t cell activity
10/10/2001EP1140112A1 Use of etherlysophospholipids as antiinflammatory agents
10/10/2001EP1140105A1 Controlled release galantamine composition
10/10/2001EP1140104A1 Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
10/10/2001EP1140102A2 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
10/10/2001EP1140101A1 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
10/10/2001EP1140099A1 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
10/10/2001EP1140098A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
10/10/2001EP1140095A1 (2-imidazoline-2-ylamino) quinoxaline derivatives for the treatment of pain
10/10/2001EP1140091A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal consitions
10/10/2001EP1140090A1 Use of phanquinone for the treatment or prevention of memory impairment
10/10/2001EP1140088A1 Controlled/modified release oral methylphenidate formulations
10/10/2001EP1140083A1 Novel compounds
10/10/2001EP1140077A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/10/2001EP1140076A1 Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome
10/10/2001EP1140074A1 Indole and indolizidine derivatives for the treatment of migraine
10/10/2001EP1140065A1 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/10/2001EP1140061A2 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
10/10/2001EP1140049A2 Compositions and methods to inactivate n-type calcium channels
10/10/2001EP1140048A2 Methods for treating certain diseases using naaladase inhibitors
10/10/2001EP1140045A2 Homer a new target of treating psychiatric disorders
10/10/2001EP1140039A1 Transparent transdermal nicotine delivery devices
10/10/2001EP1140034A1 Controlled release formulation of divalproex sodium
10/10/2001EP1140031A1 Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
10/10/2001EP1140027A1 Dosage forms comprising porous particles
10/10/2001EP1140026A1 Biodegradble polymer encapsulated serotonin receptor antagonist and method for preparing the same
10/10/2001EP1140021A1 Improved formulation for topical non-invasive application in vivo
10/10/2001EP1140011A1 Pharmaceutical composition for oral administration designed to prevent misuse at the expense of a third party
10/10/2001EP1139913A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
10/10/2001EP1139744A1 Exo-r-mecamylamine formulation and use in treatment
10/10/2001EP1139743A1 Exo-s-mecamylamine formulation and use in treatment
10/10/2001EP1083172A4 N-substituted derivatives of 5-oxyiminobarbituric acid
10/10/2001EP1051170B1 Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
10/10/2001EP0922044B1 Pyrrolo(3,2-c) quinoline derivatives
10/10/2001EP0840731B1 Polycyclic alcaloid-derivatives as nmda-receptor antagonists
10/10/2001EP0830372B1 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
10/10/2001EP0765320B1 Benzimidazolone derivatives with central dopaminergic activity
10/10/2001EP0764163B1 Tachykinin (nk 1) receptor antagonists
10/10/2001EP0667898B1 Uses of the tau/neurofilament protein kinase pk40
10/10/2001CN1317047A GBS toxin receptor
10/10/2001CN1316995A Hydroxy 2-pipecolate hydroxamide acid derivatives as MMP inhititors
10/10/2001CN1316994A Piperidine derivatives
10/10/2001CN1316993A 4,4-biarylpiperidime derivatives with opioid receptor activity
10/10/2001CN1316991A Azetidine derivatives, preparation and medicines containing them
10/10/2001CN1316911A Compositions comprising sympathomimetic amine salts unsuitable for illegal use
10/10/2001CN1316908A Neuroprotection
10/10/2001CN1316906A Stable liquid formulations of botulinum toxin
10/10/2001CN1316904A Treatment of persistent pain
10/10/2001CN1316902A Therapeutic compositions (II)
10/10/2001CN1316432A Cell death inhibitory albumen
10/10/2001CN1072670C Trans-apovincaminic acid ester derivatives as drugs
10/10/2001CN1072669C Benzimidazole compounds and their use as modulators of the GABAA receptor complex
10/10/2001CN1072668C Dihydrobenzofuran and related compounds useful and anti-inflammatory agents
10/10/2001CN1072666C (Azetidin-1-ylalkyl) lactams as tachykinin antagonists
10/10/2001CN1072664C Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compound
10/10/2001CN1072655C New Heterocyclic aminomethyl compounds, process for preparing them and pharmaceutical composition containing their
10/10/2001CN1072490C Smoke-stopping powder
10/10/2001CN1072486C Medicament for giving up narcotic drugs and stopping pain and its preparation method
10/10/2001CN1072483C Stable, ingestabl and absorbadle NADH and NADPH therapeutic compositions
10/09/2001US6300540 Genetically engineered rodent model; for use in diagnosis an treatment of alzheimer's disease
10/09/2001US6300373 Antiproliferative and neurotrophic molecules
10/09/2001US6300365 Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
10/09/2001US6300360 For therapy of stress related disorders such as post traumatic stress disorder (ptsd) as well as depression, headache and anxiety
10/09/2001US6300354 For therapy of neuroleptic diseases
10/09/2001US6300341 2-substituted heterocyclic sulfonamides
10/09/2001US6300336 Method of treating or inhibiting functional disturbances or illnesses of the lower intestinal tracts, particularly abdominal visceral pain which accompanies them
10/09/2001US6300334 Thieno[2,3-d]pyrimidine-2,4-diones
10/09/2001US6300329 Heterocyclic pyrido(1,2-a)pyrazine compounds for treatment of parkinson's disease
10/09/2001CA2215923C A method of treatment of mania and bipolar disorder
10/09/2001CA2203513C Liposome composition containing selegilin
10/09/2001CA2142320C Sustained release tablets containing bupropion
10/09/2001CA2119662C New nitrogen bicyclic derivatives, their preparation process and pharmaceutical compositions comtaining them
10/09/2001CA2016501C Substituted pyrrole compounds and their applications in pharmacy
10/07/2001CA2304906A1 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/04/2001WO2001073446A1 Alpha 7 nicotinic receptor screening assays
10/04/2001WO2001073034A2 Beta-like glycoprotein hormone polypeptide and heterodimer
10/04/2001WO2001073029A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/04/2001WO2001073002A2 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
10/04/2001WO2001072977A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
10/04/2001WO2001072960A2 Il-8 receptor antagonists
10/04/2001WO2001072839A2 Human g-protein coupled receptors
10/04/2001WO2001072838A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/04/2001WO2001072836A2 G-protein coupled receptors
10/04/2001WO2001072831A2 Immunoregulator
10/04/2001WO2001072830A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
10/04/2001WO2001072777A2 Human transcription factors
10/04/2001WO2001072762A1 Pharmaceutical compositions containing oligosaccharides and preparation thereof
10/04/2001WO2001072758A1 Tricyclic protein kinase inhibitors
10/04/2001WO2001072752A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS
10/04/2001WO2001072747A1 Crystalline form ii of cabergoline
10/04/2001WO2001072746A1 Crystalline form vii of cabergoline
10/04/2001WO2001072744A1 N-heterocyclic derivatives as nos inhibitors
10/04/2001WO2001072741A2 N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treatment of central nervous system disorders
10/04/2001WO2001072737A1 Triarylimidazole derivatives as cytokine inhibitors
10/04/2001WO2001072728A2 Novel piperazine derivatives
10/04/2001WO2001072723A1 Oxa(thia)zolidine derivative and anti-inflammatory drug
10/04/2001WO2001072714A2 Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
10/04/2001WO2001072709A1 Naphtalene derivatives and their pharmaceutical use
10/04/2001WO2001072707A2 Carbamate caspase inhibitors and uses thereof
1 ... 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 ... 1833